Martin Ho, Henry C. W. Price, Tim S. Evans, Eoin O’Sullivan
{"title":"谁制造了 mRNA 疫苗?衡量治疗创新中的分工","authors":"Martin Ho, Henry C. W. Price, Tim S. Evans, Eoin O’Sullivan","doi":"10.1038/s41587-024-02441-7","DOIUrl":null,"url":null,"abstract":"To accelerate future vaccine development, understanding the longer-term funding dynamics behind recent successes such as the USA’s Operation Warp Speed and the UK’s Vaccine Taskforce is imperative.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"42 11","pages":"1643-1648"},"PeriodicalIF":33.1000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Who made the mRNA vaccine? Measuring division of labor in therapeutic innovation\",\"authors\":\"Martin Ho, Henry C. W. Price, Tim S. Evans, Eoin O’Sullivan\",\"doi\":\"10.1038/s41587-024-02441-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To accelerate future vaccine development, understanding the longer-term funding dynamics behind recent successes such as the USA’s Operation Warp Speed and the UK’s Vaccine Taskforce is imperative.\",\"PeriodicalId\":19084,\"journal\":{\"name\":\"Nature biotechnology\",\"volume\":\"42 11\",\"pages\":\"1643-1648\"},\"PeriodicalIF\":33.1000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.nature.com/articles/s41587-024-02441-7\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.nature.com/articles/s41587-024-02441-7","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Who made the mRNA vaccine? Measuring division of labor in therapeutic innovation
To accelerate future vaccine development, understanding the longer-term funding dynamics behind recent successes such as the USA’s Operation Warp Speed and the UK’s Vaccine Taskforce is imperative.
期刊介绍:
Nature Biotechnology is a monthly journal that focuses on the science and business of biotechnology. It covers a wide range of topics including technology/methodology advancements in the biological, biomedical, agricultural, and environmental sciences. The journal also explores the commercial, political, ethical, legal, and societal aspects of this research.
The journal serves researchers by providing peer-reviewed research papers in the field of biotechnology. It also serves the business community by delivering news about research developments. This approach ensures that both the scientific and business communities are well-informed and able to stay up-to-date on the latest advancements and opportunities in the field.
Some key areas of interest in which the journal actively seeks research papers include molecular engineering of nucleic acids and proteins, molecular therapy, large-scale biology, computational biology, regenerative medicine, imaging technology, analytical biotechnology, applied immunology, food and agricultural biotechnology, and environmental biotechnology.
In summary, Nature Biotechnology is a comprehensive journal that covers both the scientific and business aspects of biotechnology. It strives to provide researchers with valuable research papers and news while also delivering important scientific advancements to the business community.